Overview

PSMA PET Response Guided SabR in High Risk Pca

Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose
Phase:
Phase 1
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Once Upon a Time Foundation
Telix Pharmaceuticals (Innovations) Pty Limited
Treatments:
Gallium 68 PSMA-11